NEW YORK (GenomeWeb News) – Genomic engineering firm EnEvolv today announced it completed its Series A financing, raising $1.7 million.

The funds will go toward expanding the Boston-based company's R&D capabilities, as well as business development activities. Venture capital firm Cultivian Sandbox Venture Partners led the round.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.